Discovering significant breakthroughs in fibrosis.

Our Mission

To bring life-changing and revolutionary treatments to patients with fibrotic diseases

Blade Therapeutics was founded on a commitment to revolutionize the treatment of debilitating, incurable fibrotic diseases that impact millions of people worldwide. We are experts in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell- and tissue-damage response leading fibrosis. Our core science is underpinned by the pioneering research of Hal Dietz, M.D., Victor A. McKusick Professor of Genetics and Medicine, Johns Hopkins University.

Our focused approach offers tremendous opportunity to produce disease-modifying, life-saving therapies. Since our founding in 2015, the Company has assembled critical leadership expertise supplemented by a world-class network of scientific, pharmaceutical and clinical advisors to enable efficient and successful drug development.

Today, we are advancing a robust pipeline of potential first- and best-in-class investigational therapies for diseases of lung (acute and chronic), liver and heart fibrosis, as well as neuro-degenerative diseases.

Our Leadership

Management Team

Wendye Robbins photo

Wendye Robbins, M.D.

President & CEO

Gary Patou photo

Gary Patou, M.D.

Chief Medical Officer

Felix Karim photo

Prabha Ibrahim, Ph.D.

Chief Technology Officer

Maria Fuentes photo

Maria Fuentes, Ph.D.

Executive Vice President of Research

Felix Karim photo

Felix Karim, Ph.D.

Executive Vice President of Business Development

photo of Daven Mody

Daven Mody

Vice President of Regulatory Affairs

photo of H. Shirley Chiang

H. Shirley Chiang

Vice President of Finance

photo of Ravi Rajagopalan

Ravi Rajagopalan

Executive Director, Drug Discovery

Board Of Directors

Mark Timney photo

Mark Timney
Chairman Of The Board For Blade

Luke Evnin photo

Luke Evnin, Ph.D.

Managing Director at MPM

Jim Scopa photo

Jim Scopa, J.D., M.B.A.

Managing Director at MPM

Cameron Wheeler photo

Cameron Wheeler, Ph.D.

Partner at Deerfield

William Slattery photo

William Slattery

Partner at Deerfield

Rana Al-Hallaq photo

Rana Al-Hallaq, Ph.D.

Senior Director And Principal
at Pfizer Ventures

photo of Lloyd Klickstein

Lloyd Klickstein, M.D., Ph.D.

Chief Scientific Officer

Wendye Robbins photo

Wendye Robbins, M.D.

President & CEO
Blade Therapeutics, Inc.

Scientific Advisors

Hal Dietz Photo

Hal Dietz, M.D.

Blade’s Founder

Oliver Eickelberg Photo

Oliver Eickelberg, M.D.

Scientific Advisor

Scott Friedman Photo

Scott Friedman, M.D.

Scientific Advisor

peter hirth Photo

Peter Hirth, Ph.D.

Scientific Advisor

Richard Hynes Photo

Richard Hynes, Ph.D.

Scientific Advisor

Mervyn Turner Photo

Mervyn Turner

Scientific Advisor

In Memoriam

John Nicholas image

John Nicholas, Ph.D

Vice President, Data Science

andrew tager image

Andrew Tager, M.D.

Scientific Advisor


mpm logo

deerfield logo

Osage University Partners logo

bristol myers squibb logo

novartis logo

pfizer ventures logo

One Ventures logo


Blade is actively seeking to in-license clinical or pre-clinical assets to expand our pipeline of products to treat fibrosis.

We are seeking to evaluate opportunities that represent a wide variety of molecular targets.

Parties developing products or technologies for fibrotic diseases that are interested in collaborating with Blade should contact our business development team. Contact:

Blade has partnered with the Scleroderma Research Foundation (SRF) to treat disorders of fibrosis, including scleroderma. Our founder, Hal Dietz, M.D., has been working closely with SRF for several years, and Blade has provided support through its research grant program.